CoChat

Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management

Open access
Wei, Shibo, Nguyen, Thanh T., Zhang, Yan, Ryu, Dongryeol, Gariani, Karim · 2023 · Frontiers in Endocrinology

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index; 27 of the 114 sources its claims cite were checked for support.

Abstract

Sarcopenic obesity is defined as the coexistence of sarcopenia and obesity in the same individual, characterized by of the co-presence of body fat accumulation and muscle loss. This condition is currently a major concern as it is associated with frailty and disabilities such as cardiovascular disease, fractures, dementia, cancer, and increased all-cause mortality. Particularly, older individuals remain at risk of sarcopenic obesity. Progress at several levels is needed to improve the global prognostic outlook for this condition, including the elaboration and implementation of a more uniform definition that may favor the identification and specification of prevalence by age group. Furthermore, improvements in the understanding of the pathogenesis of sarcopenic obesity may lead to the development of more specific therapeutic interventions to improve prognosis. We reviewed the knowledge on sarcopenic obesity and its associations with cardiovascular diseases and mortality.

Overview

CoChat Summary

TL;DR

Sarcopenic obesity—coexistence of muscle loss and excess adiposity—is associated with frailty, cardiovascular disease, and increased all-cause mortality, especially in older adults. The review emphasizes that prevalence estimates remain imprecise because no globally accepted diagnostic definition exists, and management still centers on lifestyle modification with limited evidence for pharmacological therapies.

Key findings

  • Sarcopenic obesity is linked to frailty, fractures, cardiovascular disease, cancer, dementia, hospitalization, and increased all-cause mortality; the paper states it is associated with a higher risk of cardiovascular events than sarcopenia or obesity alone.
  • Prevalence varies widely by definition: a South Korean cohort found 0.8%–22.3% in women and 1.3%–15.4% in men; the Dutch Lifelines cohort found 1.4% in women and 0.9% in men, rising to 16.7% in the 80–89 age group; a meta-analysis of 50 studies including 86,285 people found a global prevalence of 11% in adults aged 60 years.
  • Mortality risk is elevated in several studies: NHANES III women HR 1.29 (95% CI 1.03–1.60); British Regional Heart Study men HR 1.72 (95% CI 1.35–2.18); Swedish 75-year-old women HR 3.25 (95% CI 1.2–8.9); UK Biobank men with previous cardiovascular disease HR 1.47 (95% CI 1.30–1.66); and a meta-analysis of 23 studies including 50,866 individuals found pooled HR 1.21 (95% CI 1.10–1.32, p < 0.001, I² = 64.3%).
  • Management is based mainly on lifestyle modification: caloric restriction (stated as less than 750 kcal/day), high-quality protein intake (1–1.2 g/kg/day), and combined aerobic and resistance exercise; pharmacological options such as testosterone, SARMs, GLP-1 receptor agonists, myostatin/ActRII inhibitors, and anamorelin are discussed but not strongly recommended because of limited evidence.

Methods

  • Narrative review of the literature on sarcopenic obesity, covering definition, epidemiology, pathophysiology, cardiovascular disease, mortality, and management.
  • Evidence is drawn from cited cohort studies, cross-sectional studies, meta-analyses, and preclinical/clinical trials; no systematic search strategy, inclusion criteria, or formal meta-analysis is described.
  • Main analysis is a qualitative synthesis, including a table summarizing mortality results from selected cohort studies and one meta-analysis.

Limitations

  • The paper states that the absence of globally adopted common definition criteria for sarcopenic obesity impairs precise epidemiological assessment, proper patient identification, and adapted management.
  • The paper states that pathogenesis remains complex, multifactorial, and only partially elucidated; causality is difficult to establish from cross-sectional or cohort designs, and the optimal therapeutic approach remains undetermined because of limited clinical trials.
  • Evident from the text: as a narrative review, it reports no systematic search, study-selection process, risk-of-bias assessment, or quantitative synthesis; several management recommendations rely on indirect, preclinical, or non-sarcopenic-obesity-specific evidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1185221

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (A) Pathophysiology and risk factors for sarcopenic obesity development. Aging and obesity that is induced by unhealthy diet and lack of exercise will promote the development of sarcopenic obesity. Sarcopenic obesity is associated with several deleterious biological mechanisms such as insulin resistance, lipotoxicity, mitochondrial dysfunction, oxidative stress, chronic inflammation, and proteostasis. Sarcopenic obesity is characterized by adipose tissue expansion and muscle loss that cause increased pro-inflammatory cytokine levels, increased leptin, reduced adiponectin, and intramyocellular lipid deposits. Individuals with sarcopenic obesity are more at risk of several conditions such as cardiovascular disease, cancer, diabetes, fracture, and hospitalization. GDF15, Growth differentiation factor 15; FGF21, Fibroblast growth factor 21. (B) As a result of sarcopenic obesity, there is an increased risk of cardiovascular disease, cancer, diabetes, fractures, and frailty, as well as hospitalizations, morbidity and mortality, disability, and decreased quality of life.
Figure 1 (A) Pathophysiology and risk factors for sarcopenic obesity development. Aging and obesity that is induced by unhealthy diet and lack of exercise will promote the development of sarcopenic obesity. Sarcopenic obesity is associated with several deleterious biological mechanisms such as insulin resistance, lipotoxicity, mitochondrial dysfunction, oxidative stress, chronic inflammation, and proteostasis. Sarcopenic obesity is characterized by adipose tissue expansion and muscle loss that cause increased pro-inflammatory cytokine levels, increased leptin, reduced adiponectin, and intramyocellular lipid deposits. Individuals with sarcopenic obesity are more at risk of several conditions such as cardiovascular disease, cancer, diabetes, fracture, and hospitalization. GDF15, Growth differentiation factor 15; FGF21, Fibroblast growth factor 21. (B) As a result of sarcopenic obesity, there is an increased risk of cardiovascular disease, cancer, diabetes, fractures, and frailty, as well as hospitalizations, morbidity and mortality, disability, and decreased quality of life.CC BY · PubMed Central
Figure 2 Therapeutic strategies to counter-act sarcopenic development. Various therapeutic approaches are proposed against sarcopenic obesity. Caloric restriction could be considered cautiously, especially in elderly subjects associated with high-quality protein intake. Physical activity is a cornerstone in the management of sarcopenic obesity and should combine aerobic and resistance exercises. Various pharmacological treatments are considered and include myostatin inhibitors, anamorelin, vitamin D, testosterone and selective androgen receptor modulators, and weight loss therapies. ActRII, Activin type II receptor.
Figure 2 Therapeutic strategies to counter-act sarcopenic development. Various therapeutic approaches are proposed against sarcopenic obesity. Caloric restriction could be considered cautiously, especially in elderly subjects associated with high-quality protein intake. Physical activity is a cornerstone in the management of sarcopenic obesity and should combine aerobic and resistance exercises. Various pharmacological treatments are considered and include myostatin inhibitors, anamorelin, vitamin D, testosterone and selective androgen receptor modulators, and weight loss therapies. ActRII, Activin type II receptor.CC BY · PubMed Central

Verification

Claims the paper makes

18 Valid · 2 Not valid · 61 Not checked · 26 Own results and interpretations

46 more claims · 4 with their cited sources checked

Create a free account to see all 107 claims and to verify the 87 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 99 references

Cited by

See all 367

Metadata

Authors
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K.
Affiliations
  • Sungkyunkwan University (KR)
  • Gwangju Institute of Science and Technology (KR)
  • University of Geneva (CH)
Corresponding author
Gariani, Karim
Venue
Frontiers in Endocrinology
Published
2023-06-30
Volume
14
Pages
1185221-1185221
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4382788280
Cited by
291
References
98
Citations by year
2026: 100 · 2025: 132 · 2024: 56 · 2023: 3
FWCI
10.36
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research Foundation
  • National Research Foundation of Korea (2023R1A2C3006220, 2021R1A5A8029876)
  • Ministry of Science and ICT, South Korea (2021R1A5A8029876, 2023R1A2C3006220)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
Keywords
sarcopenic obesity, sarcopenia, obesity, frailty, cardiovascular disease, all-cause mortality, pathophysiology, older adults, muscle mass loss, body fat accumulation, therapeutic interventions
MeSH terms
Adipose Tissue, Cardiovascular Diseases, Humans, Obesity, Prognosis, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. https://app.cochat.ai/papers/10.3389/fendo.2023.1185221
The paper
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023). Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1185221

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.